Safety and therapeutic efficacy has been confirmed in a Phase I clinical trial in humans with advanced cancers (carcinomas and melanomas) by direct injection into tumors of a replication incompetent adenovirus expressing mda-7 (INGN 241; Ad.mda-7) (18, 19). This evidence concerns the gene IL24 and carcinoma.